| 6.88 2.68 (63.81%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 13.36  |
1-year : | 15.6 |
| Resists | First : | 11.43 |
Second : | 13.36 |
| Pivot price | 3.02 |
|||
| Supports | First : | 5.61 |
Second : | 2 |
| MAs | MA(5) : | 4.16 |
MA(20) : | 2.89 |
| MA(100) : | 4.37 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 58.5 |
D(3) : | 55.5 |
| RSI | RSI(14): 80.9 |
|||
| 52-week | High : | 11.43 | Low : | 2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ INTS ] has closed above the upper band by 31.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 11.45 - 11.5 | 11.5 - 11.53 |
| Low: | 6.2 - 6.23 | 6.23 - 6.25 |
| Close: | 6.83 - 6.88 | 6.88 - 6.92 |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Sat, 09 Dec 2023
Intensity Therapeutics rockets on positive INT230-6 data - The Pharma Letter
Fri, 08 Dec 2023
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.36% By Investing.com - Investing.com
Fri, 08 Dec 2023
Why Is Intensity Therapeutics (INTS) Stock Up 133% Today? - InvestorPlace
Fri, 08 Dec 2023
Why Is Cancer Focused Intensity Therapeutics Stock Trading Over 100% Today? - Intensity Therapeutics (NAS - Benzinga
Fri, 08 Dec 2023
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster ... - PR Newswire
Fri, 01 Dec 2023
2023-12-01 | NDAQ:INTS | Press Release | Intensity Therapeutics Inc - Stockhouse Publishing
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 15.9 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 4 (K) |
| Shares Short P.Month | 3 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.3 % |
| Return on Equity (ttm) | -151.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -9.3 |
| PEG Ratio | 0 |
| Price to Book value | 5.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|